Webinar: Biopharma Healthcare Communications in a Post COVID-19 World. What’s Next?

Vision2Voice Biopharma Communication Webinar

WEBINAR PROGAM LENGTH: 60 minutes

Most Biopharma professionals are facing an uncertain future for delivering mission critical communications and moving programs forward due to disruptions caused by the pandemic.

We’ll look at the current state of industry communications and ponder the real-world tactics needed for future progress through the perspective of industry experts who face the same challenges that you do.

Enter Your Information to View This Webinar

"*" indicates required fields

Name*
Consent*

YOUR HOST:

Dan Rehal

Daniel J. Rehal

President, Vision2Voice Healthcare Communications
Dan founded Vision2Voice Healthcare Communications in 2008 to continue his passion of connecting healthcare professionals to the resources that improve patient care. Dan understands the pharmaceutical industry from the ground up. He has his BS and MBA from the University of Iowa spending his time studying pharmacy, chemistry, and business. He ascended the ranks at Merck early in his career and eventually assumed global responsibilities at Takeda. Dan has decades of experience in both marketing and sales roles supporting a multitude of pharmaceutical brands as an award-winning Sales Representative, Training Manager,Sales Leader,Sr. Product Manager, and Commercial Leader.

SPECIAL GUESTS:

David Kendall, MD

David Kendall, MD

Chief Medical Officer, MannKind Corporation
With over two decades of healthcare experience, David Kendall has seen the industry from many perspectives, including pharmaceutical, association side and academic. Currently, he is a Chief Medical Officer of MannKind Corporation and has previously served as Vice President, Global Medical Affairs for Eli Lilly Diabetes, Associate Professor of Clinical Medicine at the University of Minnesota, and Chief Scientific and Medical Officer of the American Diabetes Association.
Jason Riley

Jason Riley

General Manager & Vice President Rare Disease Business Unit, Horizon Therapeutics
Jason Riley has over 18 years of pharmaceutical industry experience and has spent the last five years at Horizon Therapeutics overseeing metabolic diseases and the Rare Disease Business Unit. Previously, Jason was the Associate Director of Epilepsy Marketing at Lundbeck and Product Manager of Diabetes, Cardiovascular Marketing at Takeda.